Skip to Content
Morningstar

Teleflex Inc TFX

Morningstar Rating
Unlock
Stock XNYS Rating as of
$211.17 +0.06 (0.03%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Teleflex: Fair Value Estimate Revised Upward; Outlook Strong, but Acquisitions Warrant Scrutiny

Jay Lee

We are refreshing our views on Teleflex and reiterating our no-moat rating. We think its portfolio is solid and can see high-single-digit operating profit growth over the next few years. However, the firm is acquisitive, and it's unclear whether any future acquisitions will be value accretive to shareholders given our analysis of its historical returns. We've raised our fair value estimate to $225 per share from $211 due to a decrease in our cost of capital assumption.

Read Full Report

Price vs Fair Value

View History
TFX is trading at a 8% discount.
Price
$207.27
Fair Value
$852.00
Uncertainty
Medium
1-Star Price
$685.33
5-Star Price
$338.30
Economic Moat
Fvcwf
Capital Allocation
Grld

Bulls Say, Bears Say

Bulls

UroLift provides a meaningful clinical benefit in an area of unmet needs. Together with Barrigel, Telelfex has a decent chance of building a strong business in interventional urology.

Bears

Historical acquisitions have not materially improved the company's return on capital, and the pricing and performance of future acquisitions should be carefully monitored.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TFX is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$211.11
Day Range
$209.74–212.50
52-Week Range
$177.63–276.43
Bid/Ask
$206.37 / $221.73
Market Cap
$9.95 Bil
Volume/Avg
201,415 / 278,090

Key Statistics

Price/Earnings (Normalized)
15.46
Price/Sales
3.36
Dividend Yield (Trailing)
0.64%
Dividend Yield (Forward)
0.64%
Total Yield
0.64%

Company Profile

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Mid Core
Total Number of Employees
14,500
Website
https://www.teleflex.com

Competitors

Valuation

View More
Metric
TFX
BSX
MDT
Price/Earnings (Normalized)
 15.4635.5714.64
Price/Book Value
 2.245.542.03
Price/Sales
 3.367.493.26
Price/Cash Flow
 16.0232.5914.42
Price/Earnings
TFX
BSX
MDT

Financial Strength

Metric
TFX
BSX
MDT
Quick Ratio
 1.100.631.46
Current Ratio
 2.321.322.30
Interest Coverage
 5.958.418.86
Quick Ratio
TFX
BSX
MDT

Profitability

Metric
TFX
BSX
MDT
Return on Assets (Normalized)
 5.96%8.92%7.75%
Return on Equity (Normalized)
 10.10%16.33%13.75%
Return on Invested Capital (Normalized)
 7.98%11.43%9.87%
Return on Assets
TFX
BSX
MDT
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Medical Instruments & Supplies Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ISRG
Intuitive Surgical IncWbpvpbtzwcJqrf$133.8 Bil
BDX
Becton Dickinson & CoDcpgbssDpxdpg$67.6 Bil
ALC
Alcon IncHrvjzpblGmsrv$39.1 Bil
CLPBY
Coloplast A/S ADRBclkctmphCmnd$29.7 Bil
WST
West Pharmaceutical Services IncYvjgrlnpyJqdx$28.6 Bil
RMD
ResMed IncSpldzzlttzJslyzs$27.0 Bil
BAX
Baxter International IncMydmyqfcCtcqtvv$20.9 Bil
COO
The Cooper Companies IncTwgvylbmTqgfyv$18.2 Bil
HOLX
Hologic IncBcwnjqcTtccnc$17.9 Bil

Sponsor Center